Therefore, we speculate that CXCL10 could be a potential intervention target for preventing IPF in patients with hypothyroidism and emphasize that chemokines may be intermediary factors in how autoimmune diseases affect other systemic diseases. Here, CXCL10 is linked to autoimmune disease.